Logo
Press Release

Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer

Munich, Germany and Cambridge, MA, May 3, 2017 – Rigontec, the leader in RIG-I targeting RNA therapeutics, today announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. RGT100 targets t...

Continue reading ...

Rigontec GmbH raises €4.8m in a second closing of its Series A financing – Brings Series A total to €14.25m to advance RNA-based immunotherapeutics for cancer and viral diseases

Bonn, Germany. 24th March 2015 – Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, today announces it has raised €4.8 million in a second closing of its Series A financing round from Forbion Capit...

Continue reading ...

Rigontec GmbH raises €9.45m

Rigontec GmbH raises €9.45m in a first closing of a Series A financing round to advance RNA-based immunotherapeutics for cancer and viral diseases Bonn, Germany. 14th October 2014 – Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treat...

Continue reading ...